Compare Amgen, Inc. (AMGN) vs Crown Castle International Corp (CCI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Crown Castle International Corp — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Crown Castle International Corp trades at $80 (market cap $34.77B). The key difference: Amgen, Inc. is far larger — about 5.6× Crown Castle International Corp's market cap, and Crown Castle International Corp pays the higher dividend (5.34%). Which is the better fit depends on your goals.
| AMGN | CCI | |
|---|---|---|
Market Cap | $196.12B | $34.77B |
Sector | Health | Real Estate |
52-Week High | $388.16 | $113.91 |
52-Week Low | $271.18 | $74.92 |
Enterprise Value | $241.41B | $64.59B |
Dividend Yield | 2.77% | 5.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Crown Castle (CCI) trades at $79.66, up 3.89% today, but remains in a bearish technical trend with weak moving averages. The company reported mixed Q1 2026 earnings, missing EPS estimates, while revenue declined to $4.26B in 2025. Analyst consensus is divided with a $97.33 price target, and the stock offers a 5.55% dividend yield. Recent news highlights strategic shifts to a pure-play tower focus amid leadership changes.
Outlook is cautious due to high debt levels and competitive pressures, but long-term value exists if operational improvements materialize. Key risks include interest rate sensitivity and execution challenges. Investors should weigh the dividend appeal against fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Crown Castle International Corp
Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 85,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest U.S. cities. The company has a very concentrated customer base, with more than 70% of its revenue coming from the big three U.S. mobile carriers. Crown Castle operates as a real estate investment trust.
Read more on CCI →
